In a systematic overview of >20,000 patients, enoxaparin significantly reduced 30-day death or nonfatal MI compared with unfractionated heparin, with no significant excess in major bleeding.
Does enoxaparin reduce 30-day death or nonfatal MI compared to unfractionated heparin in patients with NSTE ACS?
Enoxaparin provides a statistically significant reduction in 30-day death or nonfatal MI compared with unfractionated heparin in patients with NSTE ACS, supporting its role as a preferred anticoagulant.
Enoxaparin (Lovenox; Roule-Poulenc Rorer, Inc.), a low molecular weight heparin (LMWH), is commonly used in the management of non-ST-segment elevation acute coronary syndromes (NSTE ACS) based on clinical trial outcomes. It is one of a group of glycosaminoglycan compounds that accelerate the inactivation of factor Xa by inducing a conformational change in antithrombin. In contrast to unfractionated heparin (UFH), LMWH have greater bioavailability, a more predictable anticoagulant response, longer half-life and a higher proportion of anti-factor Xa to anti-factor IIa activity. As a consequence, laboratory monitoring of the anticoagulant effect is typically unnecessary. Antithrombin therapy with LMWH or UFH has the highest-level recommendation (IA) in the 2002 professional guidelines for the management of unstable angina and non-ST-elevation myocardial infarction, where enoxaparin has a IIA recommendation over UFH unless early coronary artery bypass surgery is planned. In a recent systematic overview of > 20,000 patients with NSTE ACS from six clinical trials, including conservative and invasively managed patients, enoxaparin provided a statistically significant reduction in 30-day death or nonfatal myocardial infarction (MI) compared with UFH with no significant excess in transfusions, or major bleeding. These data support the role of enoxaparin as an anti-coagulant in patients with NSTE ACS.
Galla et al. (Wed,) conducted a review in non-ST-segment elevation acute coronary syndromes (NSTE ACS) (n=20,000). Enoxaparin vs. Unfractionated heparin (UFH) was evaluated on 30-day death or nonfatal myocardial infarction (MI). In a systematic overview of >20,000 patients, enoxaparin significantly reduced 30-day death or nonfatal MI compared with unfractionated heparin, with no significant excess in major bleeding.